ALNY
NASDAQ · Biotechnology
Alnylam Pharmaceuticals Inc
$251.65
+7.33 (+3.00%)
Financial Highlights (FY 2026)
Revenue
3.72B
Net Income
314.43M
Gross Margin
81.6%
Profit Margin
8.5%
Rev Growth
+53.0%
D/E Ratio
3.42
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 81.6% | 81.6% | 66.8% | 66.8% |
| Operating Margin | 12.4% | 11.1% | -2.9% | -3.4% |
| Profit Margin | 8.5% | 8.0% | -4.1% | -4.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.72B | 2.43B | 8.33B | 7.46B |
| Gross Profit | 3.04B | 1.99B | 5.56B | 4.98B |
| Operating Income | 460.04M | 270.65M | -243,147,328 | -252,571,019 |
| Net Income | 314.43M | 184.98M | -342,544,860 | -322,269,138 |
| Gross Margin | 81.6% | 81.6% | 66.8% | 66.8% |
| Operating Margin | 12.4% | 11.1% | -2.9% | -3.4% |
| Profit Margin | 8.5% | 8.0% | -4.1% | -4.3% |
| Rev Growth | +53.0% | +53.0% | +0.5% | +0.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 12.51B | 12.51B | 14.01B | 15.59B |
| Total Equity | 3.66B | 3.66B | 23.32B | 23.10B |
| D/E Ratio | 3.42 | 3.42 | 0.60 | 0.67 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 515.88M | 320.36M | -349,941,665 | -268,494,136 |
| Free Cash Flow | — | — | -259,812,213 | -171,989,952 |